Identifying Patients
Who in your practice would benefit from BENLYSTA?
BENLYSTA has been studied in a broad base of patients. Find out which SLE and LN patients would benefit from BENLYSTA. Here are some useful tools:
Consider evaluating your patients with SLE for BENLYSTA if:1-4
- Patient is 5 years of age or older and has been diagnosed with SLE according to the American College of Rheumatology criteria
- Patient meets at least 1 of the following:
- Antinuclear antibody (ANA) titer ≥1:80
- Anti-dsDNA autoantibodies ≥30 IU/mL
- Patient is currently receiving any of the following types of standard therapy, alone or in combination, for ≥30 days:
- Antimalarial
- Immunosuppressive
- Corticosteroid
- NSAID
- Patient has active SLE*:
- SELENA-SLEDAI score ≥6 for BLISS-52 and BLISS-76
- SELENA-SLEDAI score ≥8 for BLISS-SC
- Patient is not using other biologics
- Patient does not have severe active CNS lupus
CNS = central nervous system; LN = lupus nephritis; NSAID = nonsteroidal anti-inflammatory drug; SELENA-SLEDAI = Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index; SLE = systemic lupus erythematosus.
* Can include both clinical† and serological‡ manifestations of SLE.
† eg, arthritis, rash, hair loss.
‡ eg, decreased complement and anti-dsDNA.
Consider evaluating your patients with LN for BENLYSTA if:5
- Patient is 18 years of age or older and has been diagnosed with lupus nephritis
- Patient meets at least 1 of the following:
- Antinuclear antibody (ANA) titer ≥1:80
- Anti-dsDNA autoantibodies ≥30 IU/mL
- Patient has clinically active LN requiring induction therapy, confirmed by recent renal biopsy
- Patient is not using other biologics
- Patient does not have severe active CNS lupus
Would you consider BENLYSTA for them?
* Hypothetical patient profiles. May not be representative of all BENLYSTA patients.
Meet Laura*
Patient on antimalarial and high-dose steroid
42-year-old patient diagnosed with SLE 2 years ago with persistent arthritis and rash (SELENA-SLEDAI = 6).
Current medications
- Hydroxychloroquine 300 mg/day
- Prednisone 15 mg/day

Did you know that 53% of patients treated with BENLYSTA in 3 phase III clinical trials (BLISS-SC, BLISS-52, and BLISS-76) were not receiving immunosuppressants at baseline?1-3
Meet Ashley*
Patient with lupus nephritis
34-year-old patient diagnosed with SLE 4 years ago, recently diagnosed with lupus nephritis (renal biopsy confirmed Class III lupus nephritis).
Did you know that BENLYSTA can be used in patients with lupus nephritis?
~10 months ago, presented with the following:
- Proteinuria 2.4 g/24 hours
- Active urinary sediment
- Renal biopsy confirmed Class III LN
Induction therapy
- MMF 2 g/day orally
- 3 IV pulses of methylprednisolone 750 mg/pulse
- Followed by oral prednisone 1 mg/kg/day
Maintenance therapy
- MMF 1 g/day orally
- Prednisone 5 mg/day
MMF = mycophenolate mofetil.
Meet Sophia*
Pediatric patient with SLE
12-year-old diagnosed with SLE 3 years ago (SELENA-SLEDAI = 9).
Did you know that BENLYSTA IV can be used in patients with SLE as young as 5 years old?6
Current medications
- Hydroxychloroquine 200 mg/day
- Prednisone 7.5 mg/day
LN = lupus nephritis; SLE = systemic lupus erythematosus; SELENA SLEDAI = Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index.